Fig. 3From: The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer’s diseasePlasma phospholipid and CSF DHA at 18 months. The distribution of phospholipid and CSF DHA measurements at 18 months by baseline CSF Aβ42 tertiles in participants allocated to DHA (n = 29) is illustrated. a There was no significant difference in plasma phospholipid DHA by Aβ42 tertiles after 18 months of DHA. b and c After 18 months of DHA supplementation, there was a significant decrease in CSF DHA levels in participants in the the first Aβ42 tertile (p = 0.01 for three-way group comparison, p = 0.01 for difference between T1 and T2, and p = 0.007 for difference between T1 and T3) and a significantly lower increase in the CSF-to-plasma DHA ratio (p = 0.05 for three-way group comparison, p = 0.05 for difference between T1 and T2, and p = 0.03 for difference between T1 and T3). The groups were compared using a linear regression model. *p < 0.05 for group comparison. Aβ42 amyloid-β42, CSF cerebrospinal fluid, DHA docosahexaenoic acidBack to article page